EP1463524A4 - THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA - Google Patents

THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA

Info

Publication number
EP1463524A4
EP1463524A4 EP02797231A EP02797231A EP1463524A4 EP 1463524 A4 EP1463524 A4 EP 1463524A4 EP 02797231 A EP02797231 A EP 02797231A EP 02797231 A EP02797231 A EP 02797231A EP 1463524 A4 EP1463524 A4 EP 1463524A4
Authority
EP
European Patent Office
Prior art keywords
hodgkin
lymphoma
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02797231A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1463524A2 (en
Inventor
Maurice J Wolin
Sandra Milan
Deborah Hurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1463524A2 publication Critical patent/EP1463524A2/en
Publication of EP1463524A4 publication Critical patent/EP1463524A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02797231A 2001-12-07 2002-12-06 THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA Withdrawn EP1463524A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US17968 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
US293664 2002-11-12
PCT/US2002/039253 WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
EP1463524A2 EP1463524A2 (en) 2004-10-06
EP1463524A4 true EP1463524A4 (en) 2005-02-09

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02797231A Withdrawn EP1463524A4 (en) 2001-12-07 2002-12-06 THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA

Country Status (5)

Country Link
EP (1) EP1463524A4 (https=)
JP (1) JP2005538034A (https=)
AU (1) AU2002362098A1 (https=)
CA (1) CA2469045A1 (https=)
WO (1) WO2003049694A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
MXPA06007236A (es) * 2003-12-22 2006-08-31 Chiron Corp Uso de polimorfismos de receptor fc como diagnosticos para estrategias de tratamiento para trastornos de la respuesta inmune.
BRPI0511187A (pt) 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
JP2008530232A (ja) * 2005-02-15 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072333A1 (en) * 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072333A1 (en) * 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 2; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 250b, ISSN: 0006-4971 *
CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. AUG 1998, vol. 46, no. 6, August 1998 (1998-08-01), pages 318 - 326, ISSN: 0340-7004 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), THUMMALA ANURADHA R ET AL: "A Phase I/II study of Rituxan and interleukin 2 (IL-2) in patients with low grade or mantle cell non Hodgkins lymphoma (NHL): Preliminary results", XP001204186, Database accession no. PREV200200152443 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; June 2002 (2002-06-01), ATKINS M B: "Interleukin-2: Clinical applications", XP009041149, Database accession no. EMB-2002208050 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 1998 (1998-08-01), MEROPOL N J ET AL: "Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.", XP001204063, Database accession no. NLM9756416 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), FEHNIGER T A ET AL: "Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.", XP001204064, Database accession no. NLM10880055 *
JANAKIRAMAN N ET AL: "RITUXIMAB: CORRELATION BETWEEN EFFECTOR CELLS AND CLINICAL ACTIVITYIN NHL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 10,SUP01 PT01, 15 November 1998 (1998-11-15), pages 337A, XP001009992, ISSN: 0006-4971 *
LEGET G A ET AL: "USE OF RITUXIMAB, THE NEW FDA-APPROVED ANTIBODY", CURRENT OPINION IN ONCOLOGY, CURRENT SCIENCE LTD, US, vol. 10, no. 6, November 1998 (1998-11-01), pages 548 - 551, XP000952702, ISSN: 1040-8746 *
SEMINARS IN ONCOLOGY 2002 UNITED STATES, vol. 29, no. 3 SUPPL. 7, 2002, pages 12 - 17, ISSN: 0093-7754 *
THE JOURNAL OF CLINICAL INVESTIGATION. JUL 2000, vol. 106, no. 1, July 2000 (2000-07-01), pages 117 - 124, ISSN: 0021-9738 *
YIRINEC B ET AL: "Preliminary report on biological effects of rituxan (R) and interleukin-2 (IL-2) in patients with low-grade or mantle cell non-Hodgkins lymphoma (NHL)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 94, no. 10 suppl 1 part 2, 15 November 1999 (1999-11-15), pages 270b, XP002170813, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2002362098A8 (en) 2003-06-23
WO2003049694A3 (en) 2003-11-06
CA2469045A1 (en) 2003-06-19
AU2002362098A1 (en) 2003-06-23
JP2005538034A (ja) 2005-12-15
WO2003049694A2 (en) 2003-06-19
EP1463524A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
EP1463524A4 (en) THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA
GB2393202B (en) Methods of well treatment
AU2002348135A1 (en) Methods for the treatment of addiction
HUP0302739A3 (en) Method for the treatment of tobacco
GB0129976D0 (en) Treatment method
GB0118383D0 (en) Therapeutic methods
EP1463495A4 (en) AGENTS AND METHODS FOR TREATING CANCER
GB0124124D0 (en) Methods of treatment
GB0120147D0 (en) Treatment method
GB0112216D0 (en) Method of treatment
GB0210741D0 (en) Methods of therapy
GB0130763D0 (en) Treatment methods
GB0118892D0 (en) Method of treatment
AU2004281077A1 (en) Methods and agents for the treatment of cancer
IL161630A0 (en) Methods of treating endometreosis
GB0221712D0 (en) Methods of treatment
HK1070270A (en) Methods of therapy for non-hodgkin's lymphoma
GB0126253D0 (en) Treatment method
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002367463A8 (en) Novel p53bp2 compounds for therapy and diagnosis and methods for using same
AUPR950401A0 (en) Methods for treatment
AU2003905726A0 (en) Methods and agents for the treatment of cancer
GB0126094D0 (en) Method of treatment
GB0116029D0 (en) Method of treatment
GB0111487D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20041228

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 38/20 B

Ipc: 7A 61K 39/395 A

17Q First examination report despatched

Effective date: 20050331

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070270

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

17Q First examination report despatched

Effective date: 20050331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070270

Country of ref document: HK